Table 4.
Incidence rates (IR) and incidence rate ratios (IRR) of gynecologic visits and procedures associated with use of immunosuppressive drugs (ISD) versus hydroxychloroquine (HCQ) in a propensity-score matched analysis
| Immunosuppressive Drugs | Hydroxychloroquine | |||||||
|---|---|---|---|---|---|---|---|---|
| Number | Person- years |
IR per 1,000 person-years (95% CI) |
IRR (95% CI) |
Number | Person- years |
IR per 1,000 person-years (95% CI) |
IRR (95% CI) |
|
| Commercial Insurance Plans | ||||||||
| Outpatientgynecology visits | 2912 | 3000 | 970.82 (936.20– 10006.70) |
0.93 (0.88–0.98) |
2773 | 2655 | 1044.52 (1006.36–1084.13) |
Ref. |
| Papanicolaou tests | 566 | 3000 | 188.70 (173.77–204.9) |
1.15 (1.01–1.27) |
435 | 2655 | 163.85 (149.16–180.0) |
Ref. |
| Colposcopy | 90 | 3000 | 30.0 (24.40–36.89) |
0.93 (0.69–1.25) |
86 | 2655 | 32.39 (26.22–40.02) |
Ref. |
| Any gynecologic procedure | 679 | 3000 | 226.37 (209.97–244.05) |
1.13 (1.01–1.27) |
521 | 2655 | 200.02 (183.71–217.77) |
Ref. |
| Medicaid Insurance* | ||||||||
| Papanicolaou tests | 471 | 3621 | 130.09 (118.86–142.39) |
1.00 (0.94–1.20) |
411 | 3164 | 129.91 (117.9–143.10) |
Ref. |
| Colposcopy | 121 | 3621 | 33.42 (27.97–39.94) |
1.31 (0.99–1.74) |
81 | 3164 | 25.60 (20.59–31.83) |
Ref. |
| Any gynecologic procedure | 618 | 3621 | 170.70 (157.75–184.70) |
1.10 (0.94–1.20) |
507 | 3164 | 160.25 (146.89–174.83) |
Ref. |
*
Number of outpatient gynecologic visits is not available in Medicaid data